Asymmetric cross-inhibition between GABAA and glycine receptors in rat spinal dorsal horn neurons.
Presynaptic nerve terminals of inhibitory synapses in the dorsal horn of the spinal cord and brain stem can release both GABA and glycine, leading to coactivation of postsynaptic GABAA and glycine receptors. In the present study we have analyzed functional interactions between GABAA and glycine receptors in acutely dissociated neurons from rat sacral dorsal commissural nucleus. Although the application of GABA and glycine activates pharmacologically distinct receptors, the current induced by a simultaneous application of these two transmitters was less than the sum of currents induced by applying two transmitters separately. Sequential application of glycine and GABA revealed that the GABA-evoked current is more affected by glycine than glycine-evoked responses by GABA. Activation of glycine receptors decreased the amplitude and accelerated the rate of desensitization of GABA-induced currents. This asymmetric cross-inhibition is reversible, dependent on the agonist concentration applied, but independent of both membrane potential and intracellular calcium concentration or changes in the chloride equilibrium potential. During sequential applications, the asymmetric cross-inhibition was prevented by selective GABAA or glycine receptor antagonists, suggesting that occupation of binding sites did not suffice to induce glycine and GABAA receptors functional interaction, and receptor channel activation is required. Furthermore, inhibition of phosphatase 2B, but not phosphatase 1 or 2A, prevented GABAA receptor inhibition by glycine receptor activation, whereas inhibition of phosphorylation pathways rendered cross-talk irreversible. Taken together, our results demonstrated that there is an asymmetric cross-inhibition between glycine and GABAA receptors and that a selective modulation of the state of phosphorylation of GABAA receptor and/or mediator proteins underlies the asymmetry in the cross-inhibition.
Li
Yong
Y
Department of Neurobiology and Biophysics, University of Science and Technology of China, Hefei 230027, China.
Wu
Long-Jun
LJ
Legendre
Pascal
P
Xu
Tian-Le
TL
D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D019703:Calcineurin / Q000737:chemistry; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D018756:GABA Antagonists / Q000494:pharmacology; D005998:Glycine / Q000737:chemistry / Q000494:pharmacology; D018684:Glycine Agents / Q000494:pharmacology; D007700:Kinetics; D008564:Membrane Potentials; D010766:Phosphorylation; D020671:Posterior Horn Cells / Q000378:metabolism*; D011485:Protein Binding; D054645:Protein Phosphatase 1; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000378:metabolism*; D018009:Receptors, Glycine / Q000378:metabolism*; D015398:Signal Transduction; D013331:Strychnine / Q000494:pharmacology; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D018756:GABA Antagonists; D018684:Glycine Agents; D011963:Receptors, GABA-A; D018009:Receptors, Glycine; D005680:gamma-Aminobutyric Acid; D019703:Calcineurin; D054645:Protein Phosphatase 1; D013331:Strychnine; D002118:Calcium; D005998:Glycine; D001640:Bicuculline